Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Treprostinil 0.6 MG/ML Inhalant Solution [Tyvaso]

Known as: Tyvaso (treprostinil 1.74 MG) per 2.9 ML Inhalant Solution, TYVASO 1.74 MG/2.9 mL (0.6 MG/mL) Inhalant Solution, treprostinil 1.74 mg in 2.9 mL ORAL INHALANT [TYVASO] 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
OF OBJECTIVES Significant advantages are associated with inhaled therapies for pulmonary arterial hypertension (PAH), including… Expand
2019
2019
Summary of Objectives Inhalational drug delivery to treat PAH is attractive due to enhanced pulmonary specificity and reduced… Expand
2014
2014
Introduction : Inhaled treprostinil (Tyvaso™) for pulmonary arterial hypertension (PAH) is dosed 4 times daily. In an effort to… Expand
  • figure 3